ID   ARD-EZH2i-R
AC   CVCL_A5RY
SY   ARD_EZH2i_R; ARD-R
DR   GEO; GSM2774138
DR   GEO; GSM2774141
DR   GEO; GSM2774143
DR   GEO; GSM2774146
DR   Wikidata; Q107113377
RX   PubMed=29045832;
CC   Selected for resistance to: ChEBI; CHEBI:167693; 1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-1H-indazole-4-carboxamide (GSK343).
CC   Sequence variation: Gene deletion; HGNC; 12637; KDM6A; Zygosity=Homozygous (PubMed=29045832).
CC   Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ4 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ5 (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_XD83 ! ARD
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 10-09-24; Version: 5
//
RX   PubMed=29045832; DOI=10.1016/j.celrep.2017.09.078; PMCID=PMC5706555;
RA   Ezponda T., Dupere-Richer D., Will C.M., Small E.C., Varghese N.,
RA   Patel T., Nabet B., Popovic R., Oyer J., Bulic M., Zheng Y.-P.,
RA   Huang X.-X., Shah M.Y., Maji S., Riva A., Occhionorelli M., Tonon G.,
RA   Kelleher N.L., Keats J.J., Licht J.D.;
RT   "UTX/KDM6A loss enhances the malignant phenotype of multiple myeloma
RT   and sensitizes cells to EZH2 inhibition.";
RL   Cell Rep. 21:628-640(2017).
//